<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02958566</url>
  </required_header>
  <id_info>
    <org_study_id>825977-4</org_study_id>
    <nct_id>NCT02958566</nct_id>
  </id_info>
  <brief_title>Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery</brief_title>
  <official_title>Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois College of Medicine at Peoria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Illinois College of Medicine at Peoria</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The General Objective of this study is to investigate the cost and efficacy of treating
      patients undergoing colorectal surgical resections with an opioid limited pain control
      regimen as part of an Enhanced Recovery After Surgery (ERAS) Protocol. This group will be
      compared to a traditional opioid based pain control regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative ileus is a well-known problem for patients who have undergone a colorectal
      procedure. It is manifested as abdominal distension, accumulation of gas and fluid within the
      bowels and delayed bowel function (flatus or defecation). It is estimated that with
      traditional perioperative care for open colon resection postoperative ileus can lead to a
      length of stay (LOS) of 10 days. Such factors include the use of narcotics, immobilization,
      over-hydration with IV fluid etc. With about 350,000 colon and small bowel resections
      occurring annually and a bill to the healthcare system greater than US $20 billion, even
      decreasing LOS by one or two days can result in substantial cost savings.

      All patients undergoing colorectal surgery require medications for pain control. The mainstay
      of current treatment includes narcotics/opioids. The effect of these medicines on mu
      receptors of the intestine contribute to delayed bowel function. Protocols that limit the use
      of narcotics/opioids may reduce the risk of ileus, thus reducing length of stay and reducing
      cost.

      A prospective randomized clinical trial at a single tertiary referral academic affiliated
      medical center (OSF St. Francis Medical Center). Patients undergoing minimally invasive
      (laparoscopic or robotic) colorectal resection will be considered for inclusion. Surgery will
      be performed by two surgeons participating in the study protocol. Patient accrual is intended
      to begin May 1, 2016 and terminate either after 80 patients have been accrued or December 31,
      2018, whichever is first. Informed consent will be obtained and preoperative education will
      be provided (appendix A). Patients will be randomized to one of two groups. The randomization
      scheme is a random-permuted-block design without stratification. The block size is a random
      number between 4 and 8. Personnel who are unassociated with patient screening, enrollment, or
      follow-up will create the allocation sequence and will use a computerized, random number
      generator. The allocation sequence will be transferred to sequentially numbered, opaque
      envelopes for purposes of allocation concealment. Clinical trial coordinators/physicians will
      verify patient eligibility and informed consent before opening the envelope to obtain the
      treatment assignment. The experimental group will be placed on a narcotic limited protocol as
      described below. All used medications are FDA approved. No investigational medicines will be
      used.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>30 days</time_frame>
    <description>Total time in hospital from admission to discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Days to Return of Bowel Function</measure>
    <time_frame>30 days</time_frame>
    <description>Time from operation to first passage of flatus or bowel movement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication cost</measure>
    <time_frame>30 days</time_frame>
    <description>Total cost of inpatient medications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital stay cost</measure>
    <time_frame>30 days</time_frame>
    <description>Total cost of hospital stay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of narcotics used</measure>
    <time_frame>30 days</time_frame>
    <description>Total amount of narcotics patient consumed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>30 days</time_frame>
    <description>Death, prolonged ileus (insertion of NG tube or lack of bowel function on POD 3), respiratory failure, renal failure, SSI, leak, pneumonia, UTI, DVT/PE, cardiac event/MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>30 days</time_frame>
    <description>Measured using a survey given to patient at discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Colon Diverticulosis</condition>
  <condition>Colonic Neoplasms</condition>
  <condition>Colonic Diverticulitis</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Ileus</condition>
  <condition>Ileus Paralytic</condition>
  <condition>Ileus; Mechanical</condition>
  <condition>Constipation Drug Induced</condition>
  <condition>Constipation</condition>
  <condition>Rectum Cancer</condition>
  <condition>Rectum Neoplasm</condition>
  <arm_group>
    <arm_group_label>Narcotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine, Dilaudid or Fentanyl patient controlled anesthesia (PCA) for the immediate postoperative period, in addition to Norco 5-325 mg 1-2 tabs Q4H PRN, or equivalent medication.
Post-operative day 1: PCA will be discontinued and the patients will have IV narcotics PRN: Morphine 1-2 mg Q2H PRN, fentanyl 50-75 mcg Q2H PRN or Dilaudid 0.5 mg Q2H PRN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Narcotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gabapentin 300 mg PO, orphenadrine 60 mg IV, acetaminophen 1000 mg PO or IV on Morning of surgery. Lidocaine 100 mg prior to incision, lidocaine 1mg/kg/hour during procedure, marcaine in all incisions. Ketamine and methadone per anesthesia. Acetaminophen 1000 mg PO or IV, gabapentin 300 mg PO, tramadol 50 mg PO in PACU. Acetaminophen 600 mg PO Q 6 hours, tramadol 50 mg PO Q 6 hours, gabapentin 300 mg PO Q 6 hours, orphenadrine 60 mg IV Q 12 hours, ketorolac 15 mg IV Q 6 hours for 48 hours post-operatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <arm_group_label>Non-Narcotic</arm_group_label>
    <other_name>Tylenol</other_name>
    <other_name>Ofirmev</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <arm_group_label>Non-Narcotic</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orphenadrine</intervention_name>
    <arm_group_label>Non-Narcotic</arm_group_label>
    <other_name>Norflex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <arm_group_label>Non-Narcotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marcaine</intervention_name>
    <arm_group_label>Non-Narcotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <arm_group_label>Non-Narcotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <arm_group_label>Non-Narcotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <arm_group_label>Non-Narcotic</arm_group_label>
    <other_name>Ultram</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <arm_group_label>Non-Narcotic</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Sulfate</intervention_name>
    <arm_group_label>Non-Narcotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <arm_group_label>Non-Narcotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dilaudid</intervention_name>
    <arm_group_label>Non-Narcotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocodone-Acetaminophen Tab 5-325 MG</intervention_name>
    <arm_group_label>Non-Narcotic</arm_group_label>
    <other_name>Norco</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Sulfate</intervention_name>
    <description>PCA</description>
    <arm_group_label>Narcotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>PCA</description>
    <arm_group_label>Narcotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dilaudid</intervention_name>
    <description>PCA</description>
    <arm_group_label>Narcotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET</intervention_name>
    <description>Breakthrough</description>
    <arm_group_label>Narcotic</arm_group_label>
    <other_name>Norco</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females above the age of 18

          -  Patients undergoing laparoscopic or robotic colorectal resections

        Exclusion Criteria:

          -  History of constipation

          -  Pre-existing use of narcotics or opioids

          -  Pre-existing renal or hepatic failure

          -  Mental illness, mental retardation, or inability to participate in informed consent
             due to mental status

          -  Pre-existing dementia

          -  Allergy to any protocol medication

          -  Emergency operation

          -  Subjects who are incarcerated or wards of the state

          -  Minors

          -  Subjects with inflammatory bowel disease, active colitis, or pre-existing
             intra-abdominal inflammation. Diverticulitis without active infection/inflammation
             will not be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven S Tsoraides, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois College of Medicine at Peoria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammed Almzayyen, MD</last_name>
    <email>mohavt@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc A Sarran, MD</last_name>
    <email>marc.sarran@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uicomp</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven S Tsoraides, MD/MPH</last_name>
      <phone>309-495-0200</phone>
      <email>stsora1@uic.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Muller S, Zalunardo MP, Hubner M, Clavien PA, Demartines N; Zurich Fast Track Study Group. A fast-track program reduces complications and length of hospital stay after open colonic surgery. Gastroenterology. 2009 Mar;136(3):842-7. doi: 10.1053/j.gastro.2008.10.030. Epub 2008 Nov 1.</citation>
    <PMID>19135997</PMID>
  </results_reference>
  <results_reference>
    <citation>Serclová Z, Dytrych P, Marvan J, Nová K, Hankeová Z, Ryska O, Slégrová Z, Buresová L, Trávníková L, Antos F. Fast-track in open intestinal surgery: prospective randomized study (Clinical Trials Gov Identifier no. NCT00123456). Clin Nutr. 2009 Dec;28(6):618-24. doi: 10.1016/j.clnu.2009.05.009. Epub 2009 Jun 17.</citation>
    <PMID>19535182</PMID>
  </results_reference>
  <results_reference>
    <citation>Lubawski J, Saclarides T. Postoperative ileus: strategies for reduction. Ther Clin Risk Manag. 2008 Oct;4(5):913-7.</citation>
    <PMID>19209273</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2016</study_first_submitted>
  <study_first_submitted_qc>November 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2016</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OSF Healthcare System</investigator_affiliation>
    <investigator_full_name>Steven Tsoraides</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Surgery</investigator_title>
  </responsible_party>
  <keyword>Pain control</keyword>
  <keyword>Post-operative pain</keyword>
  <keyword>Narcotic</keyword>
  <keyword>Non-narcotic</keyword>
  <keyword>Side effect</keyword>
  <keyword>Toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Ileus</mesh_term>
    <mesh_term>Diverticulitis</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Diverticulum</mesh_term>
    <mesh_term>Diverticulitis, Colonic</mesh_term>
    <mesh_term>Diverticulosis, Colonic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Hydrocodone</mesh_term>
    <mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Orphenadrine</mesh_term>
    <mesh_term>Narcotics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

